Molecular Diagnosis & Therapy

, Volume 16, Issue 4, pp 223–234 | Cite as

Individualized Therapy for Gastroesophageal Reflux Disease

Potential Impact of Pharmacogenetic Testing based on CYP2C19
  • Takahisa Furuta
  • Mitsushige Sugimoto
  • Naohito Shirai
Leading Article

Abstract

The main therapeutic agent for gastroesophageal reflux disease (GERD) is a proton pump inhibitor (PPI). Plasma levels and the acid inhibitory effect of PPIs depend on the activity of cytochrome P450 (CYP) 2C19, which is polymorphic. Genotypes of CYP2C19 are classified into three groups: rapid metabolizers (RMs: *1/*1), intermediate metabolizers (IMs: *1/*X), and poor metabolizers (PMs: *X/*X), where *1 and X represent the wild type and the mutant allele, respectively. RMs include ultra-rapid metabolizers, who possess the CYP2C19*17 allele. The pharmacokinetics and pharmacodynamics of PPIs differ among different CYP2C19 genotype groups. Plasma PPI levels and intragastric pH values during PPI treatment are lowest in the RM group, intermediate in the IM group, and highest in the PM group. These CYP2C19-genotype-dependent differences in the pharmacokinetics and pharmacodynamics of PPIs influence the healing and recurrence of GERD during PPI treatment, suggesting the need for CYP2C19 genotype-based tailored therapy for GERD. CYP2C19 pharmacogenetics should be taken into consideration for the personalization of PPI-based therapy. However, the clinical usefulness of CYP2C19 genotype testing in GERD therapy should be verified in clinical studies.

References

  1. 1.
    Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21 (11): 953–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 Suppl. 1: 15–25.PubMedGoogle Scholar
  3. 3.
    Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121 (3): 161–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12 (4): 415–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2 (1): 25–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Sohn DR, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262 (3): 1195–202.PubMedGoogle Scholar
  7. 7.
    Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277 (2): 805–16.PubMedGoogle Scholar
  8. 8.
    Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283 (2): 434–42.PubMedGoogle Scholar
  9. 9.
    Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 18–26.PubMedCrossRefGoogle Scholar
  10. 10.
    Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20 (3): 153–67.PubMedCrossRefGoogle Scholar
  11. 11.
    The Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C19 allele nomenclature [online]. Available from URL: http://www.cypalleles.ki.se/cyp2c19.htm [Accessed 2012 Jul 17].
  12. 12.
    DeMorais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46 (4): 594–8.PubMedGoogle Scholar
  13. 13.
    deMorais SM, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58 (4): 404–11.PubMedCrossRefGoogle Scholar
  14. 14.
    deMorais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269 (22): 15419–22.PubMedGoogle Scholar
  15. 15.
    Thacker DL, Modak A, Nguyen PD, et al. Stereoselective pharmacokinetics of stable isotope (+/−)-[(13)C]-pantoprazole: implications for a rapid screening phenotype test of CYP2C19 activity. Chirality. Epub 2011 Sep 20.Google Scholar
  16. 16.
    Tazaki J, Jinnai T, Tada T, et al. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. J Atheroscler Thromb 2012; 19 (2): 186–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Kirchheiner J, Muller G, Meineke I, et al. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23 (5): 459–66.PubMedCrossRefGoogle Scholar
  18. 18.
    Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5 (6): 358–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001; 11 (4): 341–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5 (2): 181–202.PubMedCrossRefGoogle Scholar
  21. 21.
    Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005; 61 (5–6): 375–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lou HY, Chang CC, Sheu MT, et al. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2009; 65 (1): 55–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Miura M, Tada H, Yasui-Furukori N, et al. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. Chirality 2005; 17 (6): 338–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101 (7): 1467–75.Google Scholar
  25. 25.
    Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003; 98 (5): 1010–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Sheng YC, Wang K, He YC, et al. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2010; 66 (11): 1165–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Suzuki T, Matsuo K, Sawaki A, et al. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success. Epidemiol Infect 2007; 135 (1): 171–6.CrossRefGoogle Scholar
  28. 28.
    Wang H, Nie YQ, Dai SJ, et al. The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism. Zhonghua Nei Ke Za Zhi 2003; 42 (11): 777–80.PubMedGoogle Scholar
  29. 29.
    Yamano HO, Matsushita HO, Yanagiwara S. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. J Gastroenterol Hepatol 2008; 23 (4): 534–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter 2008; 13 (6): 532–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78 (6): 647–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Furuta T, Kodaira C, Nishino M, et al. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 2009; 30 (3): 294–300.PubMedCrossRefGoogle Scholar
  33. 33.
    Kodaira C, Uchida S, Yamade M, et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test. J Clin Pharmacol 2012; 52 (3): 432–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Hu YM, Xu JM, Mei Q, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol Sin 2005; 26 (3): 384–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44 (7): 297–302.PubMedGoogle Scholar
  36. 36.
    Miura M, Tada H, Yasui-Furukori N, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 2004; 60 (9): 623–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Qiao HL, Hu YR, Tian X, et al. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 2006; 62 (2): 107–12.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang Y, Zhang H, Meng L, et al. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010; 66 (6): 563–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Xie HG, Kim RB, Stein CM, et al. Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent. Br J Clin Pharmacol 1999; 48 (3): 402–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60 (6): 661–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9 (5): 539–49.PubMedCrossRefGoogle Scholar
  42. 42.
    Strom CM, Goos D, Crossley B, et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med 2012; 14 (1): 95–100.PubMedCrossRefGoogle Scholar
  43. 43.
    Rudberg I, Mohebi B, Hermann M, et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83 (2): 322–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Sugimoto K, Uno T, Yamazaki H, et al. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65 (3): 437–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79 (1): 103–13.PubMedCrossRefGoogle Scholar
  46. 46.
    Anichavezhi D, Chakradhara Rao US, Shewade DG, et al. Distribution of CYP2C19*17 allele and genotypes in an Indian population. J Clin Pharm Ther 2012; 37 (3): 313–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65 (5): 552–61.PubMedCrossRefGoogle Scholar
  48. 48.
    Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15 (12): 1929–37.PubMedCrossRefGoogle Scholar
  49. 49.
    Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intra-gastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70 (5): 484–92.PubMedCrossRefGoogle Scholar
  50. 50.
    AstraZeneca. Nexium capsule: interview form 2011 (in Japanese). Osaka: AstraZeneca, 2011.Google Scholar
  51. 51.
    Baldwin RM, Ohlsson S, Pedersen RS, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008; 65 (5): 767–74.PubMedCrossRefGoogle Scholar
  52. 52.
    Ohlsson Rosenborg S, Mwinyi J, Andersson M, et al. Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol 2008; 64 (12): 1175–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 2010; 38 (6): 894–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Gumus E, Karaca O, Babaoglu MO, et al. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 2012; 68 (5): 629–36.PubMedCrossRefGoogle Scholar
  55. 55.
    Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, et al. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006; 62 (10): 877–80.PubMedCrossRefGoogle Scholar
  56. 56.
    Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010; 69 (3): 222–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8 (8): 1685–93.PubMedCrossRefGoogle Scholar
  58. 58.
    Shirai N, Furuta T, Xiao F, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 2002; 16 (4): 837–46.PubMedCrossRefGoogle Scholar
  59. 59.
    Saitoh T, Watanabe Y, Kubo Y, et al. Effect of H2 blockers on the circadian rhythm of intragastric acidity. Biomed Pharmacother 2002; 56 Suppl. 2: 349s–352s.PubMedCrossRefGoogle Scholar
  60. 60.
    Shimatani T, Moriwaki M, Xu J, et al. Acid-suppressive effects of rabeprazole: comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis 2006; 38 (11): 802–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Miehlke S, Lobe S, Madisch A, et al. Intragastric acidity during administration of generic omeprazole or esomeprazole — a randomised, two-way crossover study including CYP2C19 genotyping. Aliment Pharmacol Ther 2011; 33 (4): 471–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Hu XP, Xu JM, Hu YM, et al. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J Clin Pharm Ther 2007; 32 (5): 517–24.PubMedCrossRefGoogle Scholar
  63. 63.
    Sagar M, Bertilsson L, Stridsberg M, et al. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 2000; 14 (11): 1495–502.PubMedCrossRefGoogle Scholar
  64. 64.
    Kita T, Tanigawara Y, Aoyama N, et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 2001; 18 (5): 615–21.PubMedCrossRefGoogle Scholar
  65. 65.
    Inamori M, Togawa JI, Takahashi H, et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol 2003; 18 (9): 1034–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Sugimoto M, Furuta T, Shirai N, et al. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2006; 80 (5): 539–48.PubMedCrossRefGoogle Scholar
  67. 67.
    Li ZS, Zhan XB, Xu GM, et al. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol 2007; 22 (6): 815–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2012; 35 (7): 810–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81 (4): 521–8.CrossRefGoogle Scholar
  70. 70.
    Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14 (10): 1259–66.PubMedCrossRefGoogle Scholar
  71. 71.
    Nishino M, Sugimoto M, Kodaira C, et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010; 55 (6): 1627–36.PubMedCrossRefGoogle Scholar
  72. 72.
    Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15 (6): 793–803.PubMedCrossRefGoogle Scholar
  73. 73.
    Shimatani T, Inoue M, Kuroiwa T, et al. Rabeprazole 10mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004; 19 (1): 113–22.PubMedCrossRefGoogle Scholar
  74. 74.
    Hayato S, Hasegawa S, Hojo S, et al. Dose-response relationships of rabeprazole 5, 10, 20, and 40mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Eur J Clin Pharmacol 2012 May; 68 (5): 579–88.PubMedCrossRefGoogle Scholar
  75. 75.
    Sugimoto M, Furuta T, Shirai N, et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005; 77 (4): 302–11.PubMedCrossRefGoogle Scholar
  76. 76.
    Sugimoto M, Furuta T, Shirai N, et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76 (4): 290–301.PubMedCrossRefGoogle Scholar
  77. 77.
    Kodaira C, Sugimoto M, Nishino M, et al. Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 2009 Jun; 65 (6): 593–600.PubMedCrossRefGoogle Scholar
  78. 78.
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 27–36.PubMedCrossRefGoogle Scholar
  79. 79.
    Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59–67.PubMedCrossRefGoogle Scholar
  80. 80.
    Zendehdel N, Biramijamal F, Hossein-Nezhad A, et al. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch Iran Med 2010; 13 (5): 406–12.PubMedGoogle Scholar
  81. 81.
    Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17 (7): 965–73.PubMedCrossRefGoogle Scholar
  82. 82.
    Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72 (4): 453–60.PubMedCrossRefGoogle Scholar
  83. 83.
    Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78 (6): 627–34.PubMedCrossRefGoogle Scholar
  84. 84.
    Ariizumi K, Ohara S, Koike T, et al. Therapeutic effects of 10mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol 2006; 21 (9): 1428–34.PubMedGoogle Scholar
  85. 85.
    Kawamura M, Ohara S, Koike T, et al. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22 (2): 222–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Furuta T, Sugimoto M, Kodaira C, et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol 2009 Jul; 65 (7): 693–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Saitoh T, Otsuka H, Kawasaki T, et al. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology 2009; 56 (91–92): 703–6.PubMedGoogle Scholar
  88. 88.
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172–80.PubMedCrossRefGoogle Scholar
  89. 89.
    Kirchheiner J, Glatt S, Fuhr U, et al. Relative potency of proton-pump inhibitors — comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65 (1): 19–31.PubMedCrossRefGoogle Scholar
  90. 90.
    Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011; 33 (2): 213–24.PubMedCrossRefGoogle Scholar
  91. 91.
    Uemura N, Inokuchi H, Serizawa H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008; 43 (9): 670–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs — TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol 2011; 46 (11): 1273–83.PubMedCrossRefGoogle Scholar
  93. 93.
    Furuta T, Shirai N, Sugimoto M, et al. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther 2005; 22 (1): 67–74.PubMedCrossRefGoogle Scholar
  94. 94.
    Xue S, Katz PO, Banerjee P, et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15 (9): 1351–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115 (6): 1335–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Kinoshita Y, Adachi K, Fujishiro H. Therapeutic approaches to reflux disease, focusing on acid secretion. J Gastroenterol 2003; 38 Suppl. 15: 13–9.PubMedGoogle Scholar
  97. 97.
    Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 1990; 12 Suppl. 2: S54–63.PubMedCrossRefGoogle Scholar
  98. 98.
    Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54 (2): 159–61.PubMedCrossRefGoogle Scholar
  99. 99.
    Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39 (8): 1671–5.PubMedCrossRefGoogle Scholar
  100. 100.
    Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14 (8): 963–78.PubMedCrossRefGoogle Scholar
  101. 101.
    Kodaira C, Uchida S, Yamade M, et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [13C]-aminopyrine breath test. J Clin Pharmacol 2012 Mar; 52 (3): 432–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52 (18): 1502–17.PubMedCrossRefGoogle Scholar
  103. 103.
    Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008; 103 (11): 2890–907.PubMedCrossRefGoogle Scholar
  104. 104.
    Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118 (18): 1894–909.PubMedCrossRefGoogle Scholar
  105. 105.
    Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008; 6 (8): 1439–41.PubMedCrossRefGoogle Scholar
  106. 106.
    Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373 (9660): 309–17.PubMedCrossRefGoogle Scholar
  107. 107.
    Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180 (7): 713–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301 (9): 937–44.PubMedCrossRefGoogle Scholar
  109. 109.
    Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70 (3): 383–92.PubMedCrossRefGoogle Scholar
  110. 110.
    O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374 (9694): 989–97.PubMedCrossRefGoogle Scholar
  111. 111.
    Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 (20): 1909–17.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Takahisa Furuta
    • 1
  • Mitsushige Sugimoto
    • 2
  • Naohito Shirai
    • 3
  1. 1.Center for Clinical ResearchHamamatsu University School of Medicine1-20-1, Handa-Yama, Higashi-Ku, HamamatsuJapan
  2. 2.First Department of MedicineHamamatsu University School of MedicineHamamatsuJapan
  3. 3.Department of GastroenterologyJA Shizuoka Kohseiren Enshu HospitalHamamatsuJapan

Personalised recommendations